Twitter Social Media is an Effective Tool for Breast Cancer Patient Education and Support: Patient-Reported Outcomes by Survey
Twitter Social Media is an Effective Tool for Breast Cancer Patient Education and Support: Patient-Reported Outcomes by Survey
复制标题
DOI：
10.2196/jmir.4721
复制
发表时间：
2015-07-01
影响因子：
7.4
通讯作者：
Landercasper, Jeffrey
中科院分区：
文献类型：
--
作者：
Attai, Deanna J.;Cowher, Michael S.;Landercasper, Jeffrey
背景：尽管有报道称乳腺癌有益处，但许多女性并不参加乳腺癌支持团体。提供支助的网上资源丰富，但缺乏关于参与效果的信息。我们报告的Twitter乳腺癌支持社区参与者survey.Objective的结果：其目的是确定社交媒体作为乳腺癌患者教育和减少焦虑的工具的有效性。方法：乳腺癌社交媒体Twitter支持社区（#BCSM）于2011年7月开始。机构审查委员会的批准与知情同意书的豁免获得了一个去识别的调查，这是张贴在Twitter上2周，并在#BCSM博客和Facebook页面。结果：有206名受访者的调查。总的来说，92.7%（191/206）为女性。受访者报告在以下领域对乳腺癌的了解有所增加：整体知识（80.9%，153/189），生存率（85.7%，162/189），转移性乳腺癌（79.4%，150/189），癌症类型和生物学（70.9%，134/189），临床试验和研究（66.1%，125/189），治疗选择（55.6%，105/189）、乳腺影像学检查（56.6%，107/189）、基因检测和风险评估（53.9%，102/189）和放射治疗（43.4%，82/189）。参与导致31.2%（59/189）寻求第二意见或将更多信息提请其治疗团队注意，71.9%（136/189）报告计划因参与而增加其外展和宣传工作。对参与前后报告的焦虑水平进行了分析：43名最初报告“高度或极度”焦虑的患者中有29名（67%）在参与后报告“低度或无”焦虑（P
Background: Despite reported benefits, many women do not attend breast cancer support groups. Abundant online resources for support exist, but information regarding the effectiveness of participation is lacking. We report the results of a Twitter breast cancer support community participant survey.Objective: The aim was to determine the effectiveness of social media as a tool for breast cancer patient education and decreasing anxiety.Methods: The Breast Cancer Social Media Twitter support community (#BCSM) began in July 2011. Institutional review board approval with a waiver of informed consent was obtained for a deidentified survey that was posted for 2 weeks on Twitter and on the #BCSM blog and Facebook page.Results: There were 206 respondents to the survey. In all, 92.7% (191/206) were female. Respondents reported increased knowledge about breast cancer in the following domains: overall knowledge (80.9%, 153/189), survivorship (85.7%, 162/189), metastatic breast cancer (79.4%, 150/189), cancer types and biology (70.9%, 134/189), clinical trials and research (66.1%, 125/189), treatment options (55.6%, 105/189), breast imaging (56.6%, 107/189), genetic testing and risk assessment (53.9%, 102/189), and radiotherapy (43.4%, 82/189). Participation led 31.2% (59/189) to seek a second opinion or bring additional information to the attention of their treatment team and 71.9% (136/189) reported plans to increase their outreach and advocacy efforts as a result of participation. Levels of reported anxiety before and after participation were analyzed: 29 of 43 (67%) patients who initially reported "high or extreme" anxiety reported "low or no" anxiety after participation (P